Trial · NCT02403323
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Open Label Extension Period | STARTED | Part 1 (OLE): Etrolizumab Only | 431 | |
| Part 1: Open Label Extension Period | STARTED | Part 1 (OLE) to Part 2 (PML SM) | 320 | |
| Part 1: Open Label Extension Period | STARTED | Part 2 (PML SM) Only | 0 | |
| Part 1: Open Label Extension Period | COMPLETED | Part 1 (OLE): Etrolizumab Only | 5 | |
| Part 1: Open Label Extension Period | COMPLETED | Part 1 (OLE) to Part 2 (PML SM) | 320 | |
| Part 1: Open Label Extension Period | COMPLETED | Part 2 (PML SM) Only | 0 | |
| Part 1: Open Label Extension Period | NOT COMPLETED | Part 1 (OLE): Etrolizumab Only | 426 | |
| Part 1: Open Label Extension Period | NOT COMPLETED | Part 1 (OLE) to Part 2 (PML SM) | 0 | |
| Part 1: Open Label Extension Period | NOT COMPLETED | Part 2 (PML SM) Only | 0 | |
| Part 2: PML Safety Monitoring Period | STARTED | Part 1 (OLE): Etrolizumab Only | 0 | |
| Part 2: PML Safety Monitoring Period | STARTED | Part 1 (OLE) to Part 2 (PML SM) | 320 | |
| Part 2: PML Safety Monitoring Period | STARTED | Part 2 (PML SM) Only | 39 | |
| Part 2: PML Safety Monitoring Period | COMPLETED | Part 1 (OLE): Etrolizumab Only | 0 | |
| Part 2: PML Safety Monitoring Period | COMPLETED | Part 1 (OLE) to Part 2 (PML SM) | 112 | |
| Part 2: PML Safety Monitoring Period | COMPLETED | Part 2 (PML SM) Only | 33 | |
| Part 2: PML Safety Monitoring Period | NOT COMPLETED | Part 1 (OLE): Etrolizumab Only | 0 | |
| Part 2: PML Safety Monitoring Period | NOT COMPLETED | Part 1 (OLE) to Part 2 (PML SM) | 208 | |
| Part 2: PML Safety Monitoring Period | NOT COMPLETED | Part 2 (PML SM) Only | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02403323/flow